Summary of baseline clinical characteristics, CSF NF-L and clinical progression data
| Cohort 1 | Cohort 2 | |||||||||
| PSP (n=33) | CBS (n=11) | MSA (n=29) | PD (n=25) | CON (n=30) | PSP (n=21) | CBS (n=11) | MSA (n=9) | PD (n=12) | CON (n=4) | |
| Gender male/female (%) | 48/52 | 57/43 | 55/45 | 64/36 | 50/50 | 81/19 | 18/82 | 89/11 | 67/33 | 25/75 |
| Age at motor symptom onset (years)—mean, SD | 65.1* 6.2 | 64.5* 8.0 | 60.2* 5.9 | 55.8‡ 8.1 | 63.6* 6.2 | 59.4* 7.8 | 61.0* 9.2 | 50.7‡ 6.0 | ||
| Age at LP (years)—mean, SD | 69.6† 5.9 | 68.4† 8.4 | 64.4† 5.8 | 67.4†‡ 9.1 | 59.8* 9.9 | 67.2* 5.7 | 64.1* 7.5 | 65.6* 8.7 | 59.9†‡ 6.1 | 65.0* 2.9 |
| Disease duration at LP (years)—mean, SD | 4.5* 2.5 | 3.9* 1.2 | 4.2* 2.2 | 11.6 6.1 | 3.6* 2.0 | 4.7* 1.9 | 4.6* 2.6 | 9.2 3.1 | ||
| PSPRS score—mean, SD | 42.0‡ 11.5 | 38.9 15.2 | 30.6‡ 9.1 | 30.4 10.8 | ||||||
| CSF NF-L concentration (ng/L)—mean, SD | 2225.2 *†‡§ 913.4 | 2268.6 *† 1291.4 | 2991.0 *†‡ 1462.2 | 963.0 † 565.8 | 630.6 * 278.9 | 3228.5 *†‡ 1611.3 | 2547.3 *†§ 1255.7 | 4671.6 *†‡ 2768.9 | 980.3 218.7 | 868.5 236.4 |
| % of subjects deceased at point of censoring | 88 | 64 | 86 | 48 | 24 | 0 | 0 | 0 | ||
| Total disease duration in deceased group (years)—mean, SD | 7.2* 2.5 | 7.0* 2.5 | 7.1* 2.4 | 13.7 6.8 | 6.0 2.3 | NA | NA | NA | ||
| No of pathologically confirmed cases | 9 PSP=9 | 2 CBD=2 | 6 MSA=5 PSP=1 | 0 | 2 PSP=2 | NA | NA | NA | ||
Only statistically significant (p<0.05) differences between continuous variables are noted from t-tests.
*vs PD in same cohort.
†vs controls in same cohort.
‡vs same measure in other cohort.
§vs MSA in same cohort.
CBS, corticobasal syndrome; CON, controls; CSF, cerebrospinal fluid; LP, lumbar puncture; MSA, multiple system atrophy; NA, data not available; NF-L, neurofilament light chain; PD, Parkinson’s disease; PSP, progressive supranuclear palsy; PSPRS, PSP rating scale.